Pliant Therapeutics, Inc.
PLRX
$1.07
-$0.01-0.93%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -33.22% | -20.56% | -7.93% | -3.01% | 0.49% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -50.36% | -32.66% | -16.24% | 5.83% | 20.66% |
| Operating Income | 50.36% | 32.66% | 16.24% | -5.83% | -20.81% |
| Income Before Tax | 48.42% | 28.99% | 12.98% | -11.63% | -28.56% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 48.42% | 28.99% | 12.98% | -11.63% | -28.56% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 48.42% | 28.99% | 12.98% | -11.63% | -28.56% |
| EBIT | 50.36% | 32.66% | 16.24% | -5.83% | -20.81% |
| EBITDA | 50.57% | 32.78% | 16.24% | -5.96% | -20.93% |
| EPS Basic | 48.99% | 29.90% | 14.19% | -9.87% | -26.35% |
| Normalized Basic EPS | 50.99% | 31.98% | 14.23% | -9.88% | -26.36% |
| EPS Diluted | 48.99% | 29.90% | 14.19% | -9.87% | -26.35% |
| Normalized Diluted EPS | 50.99% | 31.98% | 14.23% | -9.88% | -26.36% |
| Average Basic Shares Outstanding | 1.17% | 1.37% | 1.52% | 1.68% | 1.78% |
| Average Diluted Shares Outstanding | 1.17% | 1.37% | 1.52% | 1.68% | 1.78% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |